menu search

ABBV / Here's What's Driving AbbVie's (ABBV) Outperformance This Year

Here's What's Driving AbbVie's (ABBV) Outperformance This Year
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential. Read More
Posted: Nov 28 2022, 09:02
Author Name: Zacks Investment Research
Views: 103192

ABBV News  

Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever

By The Motley Fool
November 4, 2023

Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever

Companies with a track record of dividend increases have shown rewarding shareholders is a priority. If those companies also have strong free cash flo more_horizontal

Is AbbVie Stock a Buy Now?

By The Motley Fool
November 3, 2023

Is AbbVie Stock a Buy Now?

AbbVie's top and bottom lines are struggling, as anticipated. Management thinks this rough patch will be over sometime in 2025. more_horizontal

Meet the Next Trillion-Dollar Companies: Our Top 3 Picks

By InvestorPlace
November 2, 2023

Meet the Next Trillion-Dollar Companies: Our Top 3 Picks

The current five trillion-dollar companies listed on U.S. stock exchanges include Apple (NASDAQ: AAPL ), Microsoft (NASDAQ: MSFT ), Alphabet (NASDAQ: more_horizontal

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

By Zacks Investment Research
November 2, 2023

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. more_horizontal

Investor patience tested as pharmaceutical stocks take a tumble

By MarketBeat
November 1, 2023

Investor patience tested as pharmaceutical stocks take a tumble

The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmac more_horizontal

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

By Zacks Investment Research
October 31, 2023

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. more_horizontal

Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors

By The Motley Fool
October 31, 2023

Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors

Pfizer just got an approval for a drug to treat ulcerative colitis. AbbVie is still trying to consolidate its control over that market. more_horizontal

5 Solid Stocks to Watch That Recently Hiked Dividends

By Zacks Investment Research
October 31, 2023

5 Solid Stocks to Watch That Recently Hiked Dividends

AbbVie Inc. (ABBV), Exxon Mobil Corporation (XOM), Kontoor Brands, Inc. (KTB), Select Water Solutions, Inc. (WTTR) and Macatawa Bank Corporation (MCBC more_horizontal


Search within

Pages Search Results: